Literature DB >> 23073798

Activation of CD40 by soluble recombinant human CD40 ligand inhibits human glioma cells proliferation via nuclear factor-κB signaling pathway.

Yong Zhang1, Tao Huang2, Yi Hu3, Yu Wang4.   

Abstract

As CD40 transduces activation signals involved in inflammatory and immune disorders, we explored the expression and response to CD40 engagement in human glioma cell lines in this study. The CD40 expression in BT-325 and U251 cells was flow cytometrically detected. The cells were incubated with srhCD40L for 72 h to assess its effects on cell growth in vitro. TNF-α expression was quantified by real-time PCR, and protein expression was analyzed by ELISA. The I-κb mRNA was detected by RT-PCR. I-κB expression decreased after stimulation with 1 μg/mL srhCD40L, but it was upregulated after the cells were pretreated with CD40 antibody. srhCD40L significantly inhibited the proliferation of the CD40+ human glioma cells. The stimulation of CD40+ glioma cells with soluble CD40L (CD154) up-regulated the expression of TNF-α at both mRNA and protein levels. We are led to conclude that CD40L/CD40 could inhibit human glioma cells through I-κb signaling pathway. Interferon-γ can augment CD40 expression and the inhibitory effect of CD40 ligand on cell growth in vitro. These results suggest that srhCD40L may benefit the therapy strategy of glioma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23073798     DOI: 10.1007/s11596-012-1019-1

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  17 in total

Review 1.  CD40: a growing cytoplasmic tale.

Authors:  Margaret M Harnett
Journal:  Sci STKE       Date:  2004-06-09

Review 2.  CD40/CD40L dyad in the inflammatory and immune responses in the central nervous system.

Authors:  Keqiang Chen; Jian Huang; Wanghua Gong; Lingzhi Zhang; Peichu Yu; Ji Ming Wang
Journal:  Cell Mol Immunol       Date:  2006-06       Impact factor: 11.530

Review 3.  Anti-CD 40 monoclonal antibody.

Authors:  Tom Geldart; Tim Illidge
Journal:  Leuk Lymphoma       Date:  2005-08

4.  Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation.

Authors:  Ziye Sui; Shongshan Fan; Lynn Sniderhan; Elizabeth Reisinger; Angela Litzburg; Giovanni Schifitto; Harris A Gelbard; Stephen Dewhurst; Sanjay B Maggirwar
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

5.  Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia.

Authors:  Ziye Sui; Lynn F Sniderhan; Giovanni Schifitto; Richard P Phipps; Harris A Gelbard; Stephen Dewhurst; Sanjay B Maggirwar
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

6.  Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats.

Authors:  Moneeb Ehtesham; Peter Kabos; Mervin A R Gutierrez; Ken Samoto; Keith L Black; John S Yu
Journal:  J Immunother       Date:  2003 Mar-Apr       Impact factor: 4.456

7.  Efficient magnetic bead-based separation of HIV-1-infected cells using an improved reporter virus system reveals that p53 up-regulation occurs exclusively in the virus-expressing cell population.

Authors:  Michaël Imbeault; Robert Lodge; Michel Ouellet; Michel J Tremblay
Journal:  Virology       Date:  2009-08-18       Impact factor: 3.616

Review 8.  The IKK-NF-kappaB pathway: a source for novel molecular drug targets in pain therapy?

Authors:  Ellen Niederberger; Gerd Geisslinger
Journal:  FASEB J       Date:  2008-06-17       Impact factor: 5.191

9.  A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas.

Authors:  I Stamenkovic; E A Clark; B Seed
Journal:  EMBO J       Date:  1989-05       Impact factor: 11.598

10.  Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L.

Authors:  I Airoldi; S Lualdi; S Bruno; L Raffaghello; M Occhino; C Gambini; V Pistoia; M V Corrias
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

View more
  2 in total

Review 1.  Antibody-based immunotherapy for malignant glioma.

Authors:  Patrick C Gedeon; Katherine A Riccione; Peter E Fecci; John H Sampson
Journal:  Semin Oncol       Date:  2014-06-12       Impact factor: 4.929

2.  Tumor targeting using magnetic nanoparticle Hsp70 conjugate in a model of C6 glioma.

Authors:  Maxim A Shevtsov; Ludmila Y Yakovleva; Boris P Nikolaev; Yaroslav Y Marchenko; Anatolii V Dobrodumov; Kirill V Onokhin; Yana S Onokhina; Sergey A Selkov; Anastasiia L Mikhrina; Irina V Guzhova; Marina G Martynova; Olga A Bystrova; Alexander M Ischenko; Boris A Margulis
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.